Literature DB >> 10224456

IL-10 induces a Th2 cell tolerance in allergic asthma.

M Adachi1, N Oda, F Kokubu, K Minoguchi.   

Abstract

BACKGROUND: Interleukin (IL)-10 induces a long-term antigen-specific anergy in human CD4+ T cells.
METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from house dust mite (Dermatophagoides farinae, Der f)-sensitized asthmatic patients. PBMCs were stimulated with Der f antigen for 72 h immediately after purification or after 48 h of resting culture with medium, and IL-10 and IL-5 in the culture supernatant were measured. PBMCs were also stimulated with Der f antigen for 7 days either immediately after purification or after 48 h of resting culture, after which cells were collected. Secondary proliferative responses of these cells to stimulation for 3 days with Der f antigen and mitomycin C-treated PBMCs as antigen-presenting cells or with phorbol myristate acetate (PMA) plus calcium ionophore were investigated.
RESULTS: Stimulation of PBMCs with Der f antigen immediately after purification significantly increased the proliferative response and IL-5 production. Stimulation of PBMCs with Der f antigen after resting culture with medium alone for 48 h significantly decreased IL-5 production and markedly increased IL-10 production. Although activation of cells with Der f antigen immediately after purification significantly increased secondary proliferative responses, stimulation after 48 h of resting culture failed to increase secondary proliferative responses. However, proliferation recovered when cells were activated with PMA plus calcium ionophore.
CONCLUSION: These results suggest that antigen-specific Th2 cells are anergized by IL-10 and that Th2 cell tolerance may suppress eosinophilic inflammation in allergic asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224456     DOI: 10.1159/000024145

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Cytokines and the regulation of tolerance.

Authors:  J L Ferrara
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Schistosoma mansoni antigens modulate the allergic response in a murine model of ovalbumin-induced airway inflammation.

Authors:  L S Cardoso; S C Oliveira; A M Góes; R R Oliveira; L G Pacífico; F V Marinho; C T Fonseca; F C Cardoso; E M Carvalho; M I Araujo
Journal:  Clin Exp Immunol       Date:  2010-02-02       Impact factor: 4.330

3.  Alveolar macrophages from allergic lungs are not committed to a pro-allergic response and can reduce airway hyperresponsiveness following ex vivo culture.

Authors:  P Pouliot; A Spahr; E Careau; V Turmel; E Y Bissonnette
Journal:  Clin Exp Allergy       Date:  2008-01-14       Impact factor: 5.018

4.  Evaluation on the immunotherapy efficacies of synthetic peptide vaccines in asthmatic mice with group I and II allergens from Dermatophagoides pteronyssinus.

Authors:  Chaopin Li; Pengfei Xu; Haifeng Xu; Haibin Zhu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

5.  DGKα DNA vaccine relieves airway allergic inflammation in asthma model possibly via induction of T cell anergy.

Authors:  Yan Wang; Qiao Zhang; Qianli Ma; Youlan Zhang; Zhiwei Li; Changzheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

6.  Stimulation of allergen-loaded macrophages by TLR9-ligand potentiates IL-10-mediated suppression of allergic airway inflammation in mice.

Authors:  Joost L M Vissers; Betty C A M van Esch; Prescilla V Jeurink; Gerard A Hofman; Antoon J M van Oosterhout
Journal:  Respir Res       Date:  2004-11-11

7.  Indoleamine 2,3-dioxygenase 1 (ido1) is involved in the control of mouse caput epididymis immune environment.

Authors:  Aicha Jrad-Lamine; Joelle Henry-Berger; Christelle Damon-Soubeyrand; Fabrice Saez; Ayhan Kocer; Laurent Janny; Hanae Pons-Rejraji; David H Munn; Andrew L Mellor; Najoua Gharbi; Rémi Cadet; Rachel Guiton; Robert J Aitken; Joël R Drevet
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.